| Hazard Information | Back Directory | [Uses]
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 μg/mL, 1.0 μg/mL and 0.2 μg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection[1][2]. | [in vivo]
Suvizumab (15, 30 and 45 mg/kg; i.v.; single dose) attenuates viral attack and plasma viremia, and increased the number of CD4+ T cells in SHIV C2/1 infected cynomolgus monkeys with dose-dependent manner[2].
Suvizumab (45 mg/kg; i.v.; once a week for 2 months) reduces the loss of CD4 T cells in lymphoid tissue in male cynomolgus monkeys infected with simian/human immunodeficiency virus-C2/1[4].
| [IC 50]
HIV-1; HIV-189.6: 0.2 μg/mL (IC50); HIV-1MN: 0.1 μg/mL (IC50); HIV-1SF2: 1.0 μg/mL (IC50) | [References]
[1] Matsushita S, et al. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS. 2015 Feb 20;29(4):453-62. DOI:10.1097/QAD.0000000000000570
[2] Eda Y, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol. 2006 Jun;80(11):5563-70. DOI:10.1128/JVI.02095-05
[3] Yoshimura K, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS. 2006 Oct 24;20(16):2065-73. DOI:10.1097/01.aids.0000247587.31320.fe
[4] Murakami T, et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue. AIDS. 2009 Jul 31;23(12):1485-94. DOI:10.1097/QAD.0b013e32832e5331 |
|
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|